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1456evaluation of screening guidelines. A recent study by Roberts and
Stovitz (1) reported a remarkably low rate of sudden cardiac death
(SCD) in Minnesota high school athletes on the basis of analysis of
catastrophic insurance claims. The low rate of SCD was linked to a
statewide pre-participation screening process involving a standard-
ized history and physical examination conducted every 3 years (1).
However, critical examination of the study methodology raises
important concerns about the validity of the study ﬁndings and
conclusions. This letter draws attention to major ﬂaws and presents
an alternative incidence of sudden cardiac arrest (SCA) inMinnesota
high school athletes on the basis of a search of public media reports.
The authors searched catastrophic insurance claims over a
19-year period (1993 to 2012) to identify cases of SCD during high
school athletic practices and games. The reported incidence of
SCD in Minnesota high school athletes was 0.24 per 100,000
athlete-years over 19 years and 0.11 per 100,000 athlete-years over
the last decade (1). The methodology is analogous to a widely cited
1998 study that reported an incidence of SCD in Minnesota high
school athletes of 0.46 per 100,000 athlete-years (2). The study
does not include cases resulting in death outside of an ofﬁcial high
school–sponsored sporting event such as unofﬁcial training sessions
or participation with club/select teams. The report brieﬂy mentions
cases of SCA in which the persons were saved but implies they were
not athletes or at least the cases did not happen during school-
sponsored events.
The authors associate a standardized pre-participation evaluation
with the low rate of SCD, a conclusion further promoted by a
corresponding editorial (3). However, the study provides no data as
to the results of the screening evaluations performed or the cardiac
conditions identiﬁed. If the rate of cardiovascular events in Min-
nesota high school athletes is truly as low as reported, one possible
conclusion is that no cardiovascular screening of any type is actually
needed.
We conducted a review of public media reports by searching the
Parent Heart Watch database over the last 10 years of the study
period in which the authors report only a single case of SCD. The
Parent Heart Watch database tracks cases of SCA through sys-
tematic Internet search protocols. Each case was reviewed to assess
the circumstances of the event and conﬁrm participation on a
Minnesota high school athletic team.
Between 2003 and 2012, public media reports identiﬁed 13 cases
of SCA in Minnesota high school athletes (all in males), including
6 cases of SCD and 7 cases of SCA in student athletes who sur-
vived. Roberts and Stovitz (1) document 917,069 unduplicated
high school athletes in Minnesota from 2003 to 2012. Thus, the
incidence of all SCA in Minnesota high school athletes is 1.4 per
100,000 athlete-years, and the incidence of SCD 0.65 per 100,000
athlete-years. Of the 6 deaths documented in media reports, only
1 would have been eligible for death beneﬁts from an insurance
claim, yet 4 of 6 deaths occurred during sports participation. An
alarming 46% of cases (6 of 13) occurred in boys’ basketball. The
incidence of SCA in Minnesota high school boys’ basketball is
w4.7 per 100,000 athlete-years.
Search of catastrophic insurance claims is not an accuratemethod to
conduct death surveillance in athletes. The Minnesota pre-
participation evaluation did not prevent at minimum 13 cases of
SCA between 2003 and 2012. There remains no evidence that a
screening program on the basis of history and physical examina-
tion alone is effective in identifying athletes with at-risk conditions or
in preventing SCA. Reports examining only death rates will under-
estimate the incidence of life-threatening cardiovascular events andfalsely assume that current screening strategies are effective. To sug-
gest that catastrophic insurance claims are a reliable measure of inci-
dence in support of current screening strategies is unsubstantiated.
Although many questions and challenges to more intensive cardio-
vascular screening in athletes exist, we must recognize that scientiﬁc
limitations andmisinterpretations have perpetuated an underestimate
of SCA in athletes and perhaps impeded progress toward the evalu-
ation and implementation of more effective preventive programs.*Jonathan A. Drezner, MDy
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Patients With Nonvalvular
Atrial Fibrillation
Violi et al. (1) are to be commended for their large study on the
prevalence of subclinical peripheral artery disease (PAD) among
patients with nonvalvular atrial ﬁbrillation. Indeed, the ankle-
brachial index (ABI) enables the detection of a substantial subset
of individuals with asymptomatic (or with atypical symptoms of)
PAD in diverse populations, and beyond its diagnostic interest, a
low ABI is predictive for stroke, as highlighted recently in a meta-
analysis (2). Violi et al. (1) reported an even higher than expected
21% prevalence of PAD detected by an ABI 0.90, almost
doubling the proportion of patients with “vascular disease” as
deﬁned in the CHADS2-VASc (congestive heart failure [or left
ventricular systolic dysfunction]; hypertension [blood pressure
consistently >140/90 mm Hg or on hypertension medication];
age 75 years; diabetes mellitus; previous stroke, transient ischemic
attack, or thromboembolism; vascular disease [e.g., peripheral artery
disease, myocardial infarction, aortic plaque]; age 65 to 74 years; sex
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1457category [male or female]) score (i.e., myocardial infarction, com-
plex aortic plaque, and PAD), advocated by the European Society of
Cardiology guidelines on the management of atrial ﬁbrillation, to
assess the risk of stroke (3). However, we think that prior to pro-
posing the measurement of ABI in patients with nonvalvular atrial
ﬁbrillation, several issues should be discussed.
First, the main interest of the CHADS2-VASc score is to
determine whether oral anticoagulant therapy (OAC) is necessary.
The European Society of Cardiology guidelines recommend OAC
when CHADS2-VASc is 2 and prefer OAC to aspirin when the
score is 1 (3). Hence, the practical interest of ABI measurement
would be limited to those with a CHADS2-VASc score of 0 or 1 in
order to detect “missed” cases of PAD, which would lead to
increasing the score by 1 point and ultimately to revising the
anticoagulation strategy. In their study, Violi et al. (1) report high
rates of diabetes, hypertension, and history of myocardial infarction
or stroke among those with an ABI 0.90. All those variables lead
to a higher CHADS2-VASc score, so that the prevalence of
ABI 0.90 among those with a current CHADS2-VASc score at
0 or 1 should be reported to clarify its incremental value to change
anticoagulation strategy in these low-risk patients.
Second, 10% of the study population had anABI>1.40, and these
patients have apparently not been adequately taken into consider-
ation, because almost one-half of these patients do have underlying
PAD, although the deﬁnite diagnosis would need further tests as the
ABI measurement is impeded by calciﬁed arteries (4).
Finally, the accuracy of the ABI measurement in case of irregular
rhythm is unknown. It has been shown that the measurement of
arm blood pressure in this situation is associated with considerable
intra- and interobserver variability, and it is plausible to wonder at
similar poor results when making the ratio of pressures measured in
several limbs (5). The only way to moderate the level of inaccuracy
is to advocate systematically repeated measurements and to avoid
taking the crucial decision of OAC on the basis of a sole mea-
surement of the ABI.
Once these issues are addressed, we agree with Violi et al. that a
prospective study is necessary to assess the ability of the ABI to
reclassify low-risk patients and increase the CHADS2-VASc score
discrimination index to predict stroke events in case of nonvalvular
atrial ﬁbrillation. Ultimately, a trial would be necessary to clarify the
interest of OAC in patients with both low CHADS2-VASc score
and ABI.*Victor Aboyans, MD, PhD
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1990;300:162–3.ReplyAnkle-Brachial Index in
Patients With Nonvalvular
Atrial Fibrillation
We thank Dr. Aboyans and colleagues for their comments on our
paper (1) in which we reported a 21% prevalence of low (0.90)
ankle-brachial index (ABI) in a population suffering from non-
valvular atrial ﬁbrillation. The inclusion of low ABI in the deﬁ-
nition of vascular disease within the CHA2DS2-VASc (congestive
heart failure [or left ventricular systolic dysfunction]; hypertension
[blood pressure consistently >140/90 mm Hg or on hypertension
medication]; age 75 years; diabetes mellitus; previous stroke,
transient ischemic attack, or thromboembolism; vascular disease
[e.g., peripheral artery disease, myocardial infarction, aortic pla-
que]; age 65 to 74 years; sex category [i.e., female]) score sub-
stantially modiﬁed the prevalence of vascular disease, which
increased from 17.3% to 33%. This had a particular impact on the
CHA2DS2-VASc score subclasses between 0 and 1, whereby the
inclusion of a low ABI in the score resulted in a potential risk
upgrading.
Thus, 9.5% of patients in classes 0 and 1 had a low ABI; of these,
20% and 80% were CHA2DS2-VASc classes 0 and 1, respectively.
Among patients classiﬁed as CHA2DS2-VASc score 0, smoking
was the only risk factor in 29% of patients; among those classiﬁed
as CHA2DS2-VASc score 1, 43 (18%) were women, 34 (14%) aged
from 65 to 74 years, 149 (63%) were hypertensive, 5 (2%) were
diabetic, and 6 (3%) had vascular components of the “classic”
CHA2DS2-VASc score.
The presence of an ABI 1.40 can be detected in atherosclerotic
patients, particularly in those with diabetes and this usually reﬂects
tibial artery calciﬁcation and is a predictor of cardiovascular disease
and total mortality (2). An ABI 1.40 was detected in 10% of our
nonvalvular atrial ﬁbrillation patients. When patients with
ABI 1.40 were compared with those with ABI >0.90 to 1.39
(Table 1), we found that women were more prevalent in the group
of patients with normal ABI; conversely arterial hypertension and
diabetes mellitus were more frequent in patients with ABI 1.40.
Although the deﬁnite diagnosis of PAD would need further tests
as the ABI measurement is confounded by calciﬁed arteries, we will
consider the possibility to evaluate the predictive power of this
parameter in future survival analyses.
We planned this study in 2010 using the Doppler method
for the determination of the ABI and organized a training
meeting to reduce inaccuracy level. Training included demon-
stration of performance of an ABI in nonvalvular atrial
